Carcinogenesis, Vol. 22, No. 5, 717-721,
May 2001
© 2001 Oxford University Press
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION |
No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer
1 Oncology Division and
2 Population and Clinical Sciences Division, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston, Queensland, 4029 and
3 University of Queensland, St Lucia, Queensland, 4067, Australia
Epidemiological studies suggest that ovarian cancer is an endocrine-related tumour, and progesterone exposure specifically may decrease the risk of ovarian cancer. To assess whether the progesterone receptor (PR) exon 4 valine to leucine amino acid variant is associated with specific tumour characteristics or with overall risk of ovarian cancer, we examined 551 cases of epithelial ovarian cancer and 298 unaffected controls for the underlying G
T nucleotide substitution polymorphism. Stratification of the ovarian cancer cases according to tumour behaviour (low malignant potential or invasive), histology, grade or stage failed to reveal any heterogeneity with respect to the genotype defined by the PR exon 4 polymorphism. Furthermore, the genotype distribution did not differ significantly between ovarian cancer cases and unaffected controls. Compared with the GG genotype, the age-adjusted odds ratio (95% confidence interval) for risk of ovarian cancer was 0.78 (0.57–1.08) for the GT genotype, and 1.39 (0.47–4.14) for the TT genotype. In conclusion, the PR exon 4 codon 660 leucine variant encoded by the T allele does not appear to be associated with ovarian tumour behaviour, histology, stage or grade. This variant is also not associated with an increased risk of ovarian cancer, and is unlikely to be associated with a large decrease in ovarian cancer risk, although we cannot rule out a moderate inverse association between the GT genotype and ovarian cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Gayther, H. Song, S. J. Ramus, S. K. Kjaer, A. S. Whittemore, L. Quaye, J. Tyrer, D. Shadforth, E. Hogdall, C. Hogdall, et al. Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer Cancer Res., April 1, 2007; 67(7): 3027 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Pooley, C. S. Healey, P. L. Smith, P. D.P. Pharoah, D. Thompson, L. Tee, J. West, C. Jordan, D. F. Easton, B. A.J. Ponder, et al. Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 675 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Treloar, Z. Z. Zhao, T. Armitage, D. L. Duffy, J. Wicks, D. T. O'Connor, N. G. Martin, and G. W. Montgomery Association between polymorphisms in the progesterone receptor gene and endometriosis Mol. Hum. Reprod., September 1, 2005; 11(9): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Terry, I. De Vivo, L. Titus-Ernstoff, P. M. Sluss, and D. W. Cramer Genetic Variation in the Progesterone Receptor Gene and Ovarian Cancer Risk Am. J. Epidemiol., March 1, 2005; 161(5): 442 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Pearce, J. N. Hirschhorn, A. H. Wu, N. P. Burtt, D. O. Stram, S. Young, L. N. Kolonel, B. E. Henderson, D. Altshuler, and M. C. Pike Clarifying the PROGINS Allele Association in Ovarian and Breast Cancer Risk: A Haplotype-Based Analysis J Natl Cancer Inst, January 5, 2005; 97(1): 51 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berchuck, J. M. Schildkraut, R. M. Wenham, B. Calingaert, S. Ali, A. Henriott, S. Halabi, G. C. Rodriguez, D. Gertig, D. M. Purdie, et al. Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2141 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Stewart, T. D. Querec, A. R. Ochman, B. N. Gruver, R. Bao, J. S. Babb, T. S. Wong, T. Koutroukides, A. D. Pinnola, A. Klein-Szanto, et al. Characterization of a Carcinogenesis Rat Model of Ovarian Preneoplasia and Neoplasia Cancer Res., November 15, 2004; 64(22): 8177 - 8183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, M. R. Spitz, C. I. Amos, J. Lin, M. B. Schabath, and X. Wu An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology Cancer Res., March 15, 2004; 64(6): 2251 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Modugno Ovarian Cancer and Polymorphisms in the Androgen and Progesterone Receptor Genes: A HuGE Review Am. J. Epidemiol., February 15, 2004; 159(4): 319 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Wenham, J. M. Schildkraut, K. McLean, B. Calingaert, R. C. Bentley, J. Marks, and A. Berchuck Polymorphisms in BRCA1 and BRCA2 and Risk of Epithelial Ovarian Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4396 - 4403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Wenham, B. Calingaert, S. Ali, K. McClean, R. Whitaker, R. Bentley, J. M. Lancaster, J. Schildkraut, J. Marks, and A. Berchuck Matrix Metalloproteinase-1 Gene Promoter Polymorphism and Risk of Ovarian Cancer Reproductive Sciences, September 1, 2003; 10(6): 381 - 387. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Lancaster, R. M. Wenham, S. Halabi, B. Calingaert, J. R. Marks, P. G. Moorman, R. C. Bentley, A. Berchuck, and J. M. Schildkraut No Relationship between Ovarian Cancer Risk and Progesterone Receptor Gene Polymorphism in a Population-based, Case-Control Study in North Carolina Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 226 - 227. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Spurdle, J. L. Hopper, X. Chen, M. R. E. McCredie, G. G. Giles, D. J. Venter, M. C. Southey, and G. Chenevix-Trench The Progesterone Receptor Exon 4 Val660Leu G/T Polymorphism and Risk of Breast Cancer in Australian Women Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 439 - 443. [Abstract] [Full Text] [PDF]
|
|